U.S. markets closed

Amicus Therapeutics, Inc. (FOLD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
14.40-0.28 (-1.91%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close14.68
Bid14.40 x 2900
Ask14.41 x 2200
Day's Range14.19 - 14.64
52 Week Range6.25 - 16.13
Avg. Volume2,915,495
Market Cap3.727B
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-1.14
Earnings DateNov 09, 2020 - Nov 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Amicus Therapeutics Inc (FOLD) Q2 2020 Earnings Call Transcript
    Motley Fool

    Amicus Therapeutics Inc (FOLD) Q2 2020 Earnings Call Transcript

    Thank you for joining our conference call to discuss Amicus Therapeutics' second quarter 2020 financial results and corporate highlights. Speaking on today's call, we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; and Dr. Jeff Castelli, Chief Development Officer.

  • Amicus Therapeutics (FOLD) Reports Q2 Loss, Misses Revenue Estimates

    Amicus Therapeutics (FOLD) Reports Q2 Loss, Misses Revenue Estimates

    Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Recap: Amicus Therapeutics Q2 Earnings

    Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 44.44% year over year to ($0.20), which beat the estimate of ($0.26).Revenue of $62,353,000 rose by 41.29% from the same period last year, which missed the estimate of $62,380,000.Outlook The upcoming fiscal year's revenue expected to be between $250,000,000 and $260,000,000.Conference Call Details Date: Aug 10, 2020Time: 08:30 AMView more earnings on FOLDET Webcast URL: https://edge.media-server.com/mmc/p/fvhk9nzfPrice Action Company's 52-week high was at $16.13Company's 52-week low was at $6.25Price action over last quarter: Up 32.05%Company Profile Amicus Therapeutics Inc is a biotechnology company. It is focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. Amicus Therapeutics is expanding a pipeline of medicines for rare metabolic diseases, including an industry- leading rare disease gene therapy portfolio.See more from Benzinga * Earnings Scheduled For August 10, 2020 * Stocks That Hit 52-Week Highs On Wednesday * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.